The latest update is out from TELA Bio ( (TELA) ).
TELA Bio reported a record $19 million in third-quarter revenue for 2024, marking a 26% increase from the previous year, driven by heightened demand for its OviTex products and successful public offering. The company anticipates reducing operating expenses by up to $10 million in 2025 and maintains its revenue forecast amid potential disruptions from IV fluid shortages. With a strengthened financial position, TELA Bio aims for profitability while continuing to innovate in soft-tissue reconstruction solutions.
See more insights into TELA stock on TipRanks’ Stock Analysis page.
